A LOOK AT REAL-WORLD DME TREATMENT OUTCOMES
Dr. Thomas Ciulla, MD, MBA
Using Vestrum’s 800,000 patient database, Dr. Ciulla found with Vestrum that DME patients gained about 6 letters of visual acuity at 1 year, not the average 11-letter gain seen in large randomized clinical trials. There was no difference in visual acuity outcomes among the three cohorts, and there was also no difference in performance or efficacy between the anti-VEGF agents used—bevacizumab (Avastin, Genentech), ranibizumab (Lucentis, Genentech), or aflibercept (Eylea, Regeneron). Patients who started with better visual acuity tended to experience greater vision loss, likely related to ceiling effect.
Presented at the ASRS 2017 Annual Meeting, Boston, MA; related article found in New Retina MD – December 2017